Apparent failure of moxifloxacin to prevent ciprofloxacin- and levofloxacin-susceptible Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation [6]

Clinical Infectious Diseases

Volumn 38, Issue 7, 2004, Pages 1043-1045

  Prabhu, Rajesh M ^a   Elliott, Michalle A ^a   Patel, Robin ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; OFLOXACIN; QUINOLINE DERIVATIVE;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTEREMIA; BLOOD CULTURE; CLINICAL ARTICLE; FEMALE; HUMAN; IN VITRO STUDY; LETTER; MALE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TREATMENT FAILURE; DRUG EFFECT; GRAM NEGATIVE INFECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MICROBIOLOGICAL EXAMINATION; MIDDLE AGED;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BACTEREMIA; CIPROFLOXACIN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEUTROPENIA; OFLOXACIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUINOLINES; TREATMENT FAILURE;

EID: 1842450913     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/382706     Document Type: Letter

References (5)

1. Patrick CC. Use of fluoroquinolones as prophylactic agents in patients with neutropenia. Pediatr Infect Dis J 1997; 16:135-9, 160-2.
2. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33:223 3-9.
3. Milatovic D, Schmitz FJ, Brisse S, Verhoef J, Fluit AC. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrobial Agents Chemother 2000; 44:1102-7.
4. Akasaka T, Tanaka M, Yamaguchi A, Sato K. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrobial Agents Chemother 2001; 45:2263-8.
5. Piddock LJ, Johnson M, Ricci V, Hill SL. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Antimicroh Agents Chemother 1998; 42:2956-60.